Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Usage of baicalin for preparing pharmaceuticals for preventing and treating aquatic livestock streptococcicosis

A technology of baicalin and animal chains, which is applied in the direction of antibacterial drugs, pharmaceutical formulas, and medical preparations containing active ingredients, etc. It can solve the problems of high probability of drug-resistant mutations and restrictions on the application of bacterial disease prevention and treatment in aquatic animals.

Inactive Publication Date: 2018-05-25
HAINAN UNIVERSITY
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the research on the natural compounds of Chinese herbal medicines that directly inhibit and kill pathogenic bacteria has become a research hotspot. However, due to the pressure of survival, pathogenic bacteria have a high probability of drug-resistant mutations to compounds with inhibitory and killing activities, which limits their application in the prevention and treatment of bacterial diseases in aquatic animals.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Usage of baicalin for preparing pharmaceuticals for preventing and treating aquatic livestock streptococcicosis
  • Usage of baicalin for preparing pharmaceuticals for preventing and treating aquatic livestock streptococcicosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] Example 1: Inhibitory activity of baicalin on pathogenic factor β-hemolysis / cytolysin of Streptococcus agalactiae

[0018] According to 1% inoculum volume, the OD 620nm Each of the test bacterial suspensions of 1.2 was inserted into the brain heart infusion medium (BHI) containing 0 μg / mL (blank control) and 4 μg / mL baicalin, cultured with shaking for 6 h, centrifuged at 3500 r / min for 5 min, and collected Bacteria, resuspended in 0.01mmol / L PBS (pH7.4), OD 620nm Measure the concentrated light absorbance value of the bacterial suspension, and calculate the growth inhibition rate of the drug on each test bacterium; use the double gradient dilution method to measure the half-hemolytic concentration of the bacterial suspension in each group, perform parallel detection 3 times, and take the average value to calculate 4 μg / Inhibition rate of mL baicalin on the β-hemolytic activity of the test bacteria. The results are shown in Table 1. Baicalin has an inhibitory effect on...

Embodiment 2

[0025] Example 2: The curative effect of baicalin on tilapia streptococcosis agalactiae

[0026] Select healthy tilapias with a body length of (10±2) cm and a weight of (25±5) g, and raise them temporarily in glass tanks (1m×0.5m×0.25m) for 7 days, 20 fish in each tank, for 24 hours continuously Oxygenation, feed 2% of the fish body weight every day, change the water once every 3 days, and change the water volume 1 / 3 each time, the water body temperature is (34 ± 2) ° C, divide the tilapias that have been temporarily raised into blank groups, The control group and the experimental group were divided into three groups, each group had one tank, and the concentration of tilapia in the control group and the experimental group was injected intraperitoneally at 7.5×10 7 cfu / mL Streptococcus agalactiae PBSA0901 bacterial suspension 200μL, the blank group was intraperitoneally injected with PBS 200μL, 2h later, the tilapia in the experimental group were fed with 0.445g / kg baicalin fee...

Embodiment 3

[0029] Example 3: Inhibitory effect of baicalin on β-hemolysis / cytolysin activity of Streptococcus agalactiae

[0030] OD 620nm Streptococcus agalactiae PBSA0901 bacterial suspension of 1.2 was streaked on the blood plate to observe the colony hemolysis circle; 620nm The 1.2 Streptococcus agalactiae PBSA0901 bacterial suspension was respectively inserted into the brain heart infusion medium containing 0 μg / ml (blank control) and 39.06 μg / mL baicalin (experimental group), and each group was paralleled for 3 experiments, and cultured with shaking 6h, measure the absorbance value at 620nm, calculate the growth inhibition rate of baicalin on Streptococcus agalactiae PBSA0901, streak the bacterial suspension on the blood plate, observe the hemolytic circle of the colony; continuously pass the bacterial suspension of the blank control group and the experimental group for 4 generations , for each generation, measure the absorbance value at 620nm, calculate the growth inhibition rate...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of the bacterial disease control and prevention of the aquatic livestock, and relates to a usage of baicalin for preparing pharmaceuticals for preventing and treating aquatic livestock streptococcicosis, and discloses a usage of the baicalin for inhibiting activity of tilapia-sourced streptococcus agalactiae Beta-hemolysis / cytolysin. The baicalin is applied for preparing the pharmaceuticals for preventing and treating the bacteriosis of aquatic culture animals, especially the prevention and control pharmaceuticals for tilapia streptococcus diseases, and the pharmaceuticals have the remarkable curative effect. The baicalin is a flavonoid active ingredient extracted and separated from dried roots of dicotyledonous labiate scutellaria baicalensis, and is developed as a new drug for preventing and treating the tilapia-sourced streptococcus. The baicalin has the advantages of abundant sources, low cost, low drug resistance probability, low residual risk, small toxic and side effect, environment-friendliness, no pollution, no harm and remarkable curative effect, and has the extensive application prospect.

Description

technical field [0001] The invention belongs to the technical field of prevention and control of bacterial diseases of aquaculture animals, and specifically relates to the application field of baicalin as an active ingredient in the preparation of drugs for the prevention and treatment of bacterial diseases of aquatic animals, especially the application of baicalin in the preparation of agalactiae chains of aquaculture animals as an active ingredient. The field of application of drugs for the prevention and treatment of coccidiosis. Background technique [0002] Streptococcus agalactiae (Streptococcus agalactiae) is a Gram-positive opportunistic pathogenic bacterium, which is a zoonotic bacterium of humans, animals and fish. In terms of harm to aquatic animals, it infects tilapia, rainbow trout, channel cattail, flounder and A variety of freshwater aquaculture fish such as multi-rake are the most harmful to warm-water fish, especially tilapia. In 2009, streptococcal disease...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7048A61P31/04
CPCA61K31/7048
Inventor 郭伟良周永灿王菲钟志鸿王世锋孙云
Owner HAINAN UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com